JP4630914B2 - 肝線維化抑制剤 - Google Patents
肝線維化抑制剤 Download PDFInfo
- Publication number
- JP4630914B2 JP4630914B2 JP2008105101A JP2008105101A JP4630914B2 JP 4630914 B2 JP4630914 B2 JP 4630914B2 JP 2008105101 A JP2008105101 A JP 2008105101A JP 2008105101 A JP2008105101 A JP 2008105101A JP 4630914 B2 JP4630914 B2 JP 4630914B2
- Authority
- JP
- Japan
- Prior art keywords
- liver
- group
- tgf
- liver fibrosis
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
(試験例1)
6週齢のWister系雄ラットに40%四塩化炭素含有オリーブ油またはオリーブ油のみを週2回、8週間にわたり3mL/kgずつ皮下投与した。また、前述の一般式(1)で示されるハイドロキノン誘導体のうち、2,3,5−トリメチルハイドロキノン−1−ヘキシルエーテル(化合物1)を飲用水に0.3mg/mLの濃度に溶かして、四塩化炭素の投与と平行して毎日与えた群と水のみを与えた群を設定した。すなわち、オリーブ油投与群、オリーブ油+化合物1投与群、四塩化炭素投与群、四塩化炭素+化合物1投与群の4群構成とし、各群に10匹の動物を配した。動物は四塩化炭素投与開始後8週目に屠殺し、検査を行った。検査項目として、Naofenに対する血清中の抗体価をELISA法により測定するとともに、肝臓中のNaofenのmRNA発現量をRT−PCR法により測定した。
化合物1の濃度を0.1mg/mLとした他は、試験例1と同様の条件でラット四塩化炭素誘発肝硬変モデルとした。検査項目として、肝障害の指標となる血中AST、ALT、アルブミン(ALB)、総ビリルビン(T−Bil)および肝線維化マーカーであるヒアルロン酸(HA)濃度の測定、剖検、体重および臓器重量の測定、肝細胞中のTGF−β1mRNAおよびI型コラーゲンα1mRNA発現量のRT−PCR法による測定ならびに病理組織学的検査を行った。
Claims (2)
- (A)一般式
(式中、R1は炭素数4〜8のアルキル基、R2は水素原子、炭素数2〜6のアルキルカルボニル基または炭素数2〜6のアルコキシカルボニル基を示す。)で表される化合物からなるハイドロキノン誘導体を有効成分として含み、Naofenの発現を抑制する作用を有することを特徴とする肝線維化抑制剤。 - 化1で表される化合物が2,3,5−トリメチルハイドロキノン−1−ヘキシルエーテルまたは2,3,5−トリメチルハイドロキノン−1−ヘキシルエーテル 4−アセテートである請求項1に記載の肝線維化抑制剤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008105101A JP4630914B2 (ja) | 2008-04-14 | 2008-04-14 | 肝線維化抑制剤 |
ES09157413T ES2382522T3 (es) | 2008-04-14 | 2009-04-06 | Inhibidor de fibrosis hepática |
AT09157413T ATE547100T1 (de) | 2008-04-14 | 2009-04-06 | Leberfibroseinhibitor |
EP09157413A EP2110127B1 (en) | 2008-04-14 | 2009-04-06 | Hepatic Fibrosis Inhibitor |
US12/385,603 US20090270654A1 (en) | 2008-04-14 | 2009-04-14 | Hepatic fibrosis inhibitor |
CN2009101335571A CN101559049B (zh) | 2008-04-14 | 2009-04-14 | 肝纤维化抑制剂 |
US12/591,982 US7847132B2 (en) | 2008-04-14 | 2009-12-07 | Hepatic fibrosis inhibitor |
HK10103708.5A HK1135619A1 (en) | 2008-04-14 | 2010-04-16 | Hepatic fibrosis inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008105101A JP4630914B2 (ja) | 2008-04-14 | 2008-04-14 | 肝線維化抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009256226A JP2009256226A (ja) | 2009-11-05 |
JP4630914B2 true JP4630914B2 (ja) | 2011-02-09 |
Family
ID=40910281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008105101A Active JP4630914B2 (ja) | 2008-04-14 | 2008-04-14 | 肝線維化抑制剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20090270654A1 (ja) |
EP (1) | EP2110127B1 (ja) |
JP (1) | JP4630914B2 (ja) |
CN (1) | CN101559049B (ja) |
AT (1) | ATE547100T1 (ja) |
ES (1) | ES2382522T3 (ja) |
HK (1) | HK1135619A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015093579A1 (ja) * | 2013-12-20 | 2015-06-25 | 株式会社日本ハイポックス | 糖尿病性腎症の予防又は治療剤 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2932977A4 (en) | 2012-12-12 | 2016-08-10 | Prism Pharma Co Ltd | PREVENTIVE OR TREATMENT AGENT FOR LIVER FIBROSIS |
WO2016170704A1 (ja) * | 2015-04-23 | 2016-10-27 | 株式会社日本ハイポックス | 慢性呼吸器疾患治療剤及び心臓の線維化抑制組成物 |
CA3013630A1 (en) | 2016-02-10 | 2017-08-17 | Wake Forest University Health Sciences | Model system of liver fibrosis and method of making and using the same |
KR102013574B1 (ko) * | 2018-10-25 | 2019-08-23 | 주식회사 바이오톡스텍 | 하이드로퀴논 유도체를 포함하는 비만 또는 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
WO2021029656A1 (ko) * | 2019-08-14 | 2021-02-18 | 주식회사 바이오톡스텍 | 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0867627A (ja) * | 1994-08-31 | 1996-03-12 | Nippon High Potsukusu:Kk | 肝疾患治療用組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2983317B2 (ja) | 1991-03-28 | 1999-11-29 | 株式会社日本ハイポックス | 新規ハイドロキノン誘導体 |
EP0589069B1 (en) * | 1992-09-18 | 1997-01-29 | Nippon Hypox Laboratories Incorporated | Hydroquinone derivatives and antioxidants and tumor inhibitors containing them |
JPH06100441A (ja) | 1992-09-22 | 1994-04-12 | Nippon High Potsukusu:Kk | ハイドロキノン誘導体含有発ガン阻止剤 |
ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
JP4749562B2 (ja) | 2001-02-16 | 2011-08-17 | 株式会社日本ハイポックス | ハイドロキノン誘導体および動脈硬化治療用組成物 |
JP2004352661A (ja) | 2003-05-29 | 2004-12-16 | Nippon Hypox Lab Inc | 難治性炎症性疾患治療剤 |
JP3700854B2 (ja) | 2003-07-24 | 2005-09-28 | 正 桂巻 | 線維化抑制剤 |
JP2005343889A (ja) | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
-
2008
- 2008-04-14 JP JP2008105101A patent/JP4630914B2/ja active Active
-
2009
- 2009-04-06 ES ES09157413T patent/ES2382522T3/es active Active
- 2009-04-06 AT AT09157413T patent/ATE547100T1/de active
- 2009-04-06 EP EP09157413A patent/EP2110127B1/en active Active
- 2009-04-14 CN CN2009101335571A patent/CN101559049B/zh active Active
- 2009-04-14 US US12/385,603 patent/US20090270654A1/en not_active Abandoned
- 2009-12-07 US US12/591,982 patent/US7847132B2/en active Active
-
2010
- 2010-04-16 HK HK10103708.5A patent/HK1135619A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0867627A (ja) * | 1994-08-31 | 1996-03-12 | Nippon High Potsukusu:Kk | 肝疾患治療用組成物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015093579A1 (ja) * | 2013-12-20 | 2015-06-25 | 株式会社日本ハイポックス | 糖尿病性腎症の予防又は治療剤 |
JPWO2015093579A1 (ja) * | 2013-12-20 | 2017-03-23 | 株式会社日本ハイポックス | 糖尿病性腎症の予防又は治療剤 |
Also Published As
Publication number | Publication date |
---|---|
ATE547100T1 (de) | 2012-03-15 |
JP2009256226A (ja) | 2009-11-05 |
US7847132B2 (en) | 2010-12-07 |
ES2382522T3 (es) | 2012-06-11 |
HK1135619A1 (en) | 2010-06-11 |
EP2110127A1 (en) | 2009-10-21 |
CN101559049A (zh) | 2009-10-21 |
US20100184858A1 (en) | 2010-07-22 |
CN101559049B (zh) | 2012-02-29 |
US20090270654A1 (en) | 2009-10-29 |
EP2110127B1 (en) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4630914B2 (ja) | 肝線維化抑制剤 | |
AU2015320792B2 (en) | Methods of treating liver disease | |
JP6846392B2 (ja) | 選択的s1p1レセプターアゴニストを含む薬学的合剤 | |
EP1978947B1 (en) | Nitrooxyderivatives for use in the treatment of muscular dystrophies | |
KR20180073597A (ko) | 혼합 이상지질혈증의 치료 | |
KR102098032B1 (ko) | 지질 이상증 치료제 | |
EP1982708A1 (en) | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanaediol derivative as active ingredient, and method for treatment of inflammatory bowel disease | |
WO1995014384A1 (en) | Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds | |
MX2011001426A (es) | Metodos para tratar la talasemia. | |
KR20180098222A (ko) | 활성화된 지방산의 치료학적 유효량을 이용한 질환의 예방, 치료 및 역행 | |
EP3091972B1 (en) | Method of treating liver disorders | |
KR101042697B1 (ko) | 간섬유화 억제제 | |
JP5198827B2 (ja) | 神経変性疾患治療薬 | |
ITMI20011744A1 (it) | Farmaci per le vasculopatie | |
KR20080081351A (ko) | 간장 질환 치료제 및 간기능 개선제 | |
WO2020175597A1 (ja) | 組織線維化による疾患の予防又は治療のための医薬 | |
KR20080072579A (ko) | 비만 예방 및/또는 치료약 | |
JP2000511550A (ja) | リポタンパク質(a)の血漿水準を低下させるための薬剤の製造のための、ラロキシフェン及び類縁化合物の使用 | |
CA2496637C (en) | Treatment of inflammatory conditions of the intestine using high density lipoprotein | |
JP2005035895A (ja) | 高カルシウム血症および骨疾患治療剤 | |
KR20140113063A (ko) | 알파 리포산의 방사선 유발 섬유증 예방 또는 치료 용도 | |
JPH08508013A (ja) | 平滑筋細胞増殖の阻害についてのカルバゾリル−▲(4)▼−オキシプロパノールアミン化合物の使用および該化合物を用いる治療法 | |
JP2005053890A (ja) | アディポネクチン濃度低下及び/又はc反応性蛋白濃度上昇及び/又はil−18濃度上昇に起因する疾患の予防及び/又は治療剤。 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100830 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101102 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101115 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131119 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4630914 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |